April 9th, 2015
Manesh R. Patel discusses his research group’s retrospective analysis of data on digoxin use among patients with atrial fibrillation in the ROCKET AF trial.
February 24th, 2014
Wes Fisher attempts to figure out what the latest marketing phrase – non-valvular atrial fibrillation – really means.
January 17th, 2013
Two experts discuss the evolving landscape of novel anticoagulants for patients with AF. Do you agree with their perspectives? What questions do you have? What has your experience taught you?
October 6th, 2011
Rivaroxaban (Xarelto, Bayer and Johnson & Johnson) is in the news today. In a rare move, the AHA has added the ATLAS ACS 2-TIMI 51 trial to its roster of Late-Breaking Clinical Trials to be presented next month at the AHA’s Scientific Sessions in Orlando. C. Michael Gibson will present the results on Sunday, November 13, at 5:13 PM. Last week, Bayer […]